KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Non-Current Assets (2016 - 2025)

AbbVie (ABBV) has disclosed Non-Current Assets for 14 consecutive years, with $104.9 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 4.27% to $104.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $426.7 billion through Dec 2025, down 3.76% year-over-year, with the annual reading at $104.9 billion for FY2025, 4.27% down from the prior year.
  • Non-Current Assets for Q4 2025 was $104.9 billion at AbbVie, roughly flat from $105.4 billion in the prior quarter.
  • The five-year high for Non-Current Assets was $123.9 billion in Q1 2021, with the low at $101.7 billion in Q4 2023.
  • Average Non-Current Assets over 5 years is $111.3 billion, with a median of $109.8 billion recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 214.22% in 2021, then fell 8.89% in 2025.
  • Over 5 years, Non-Current Assets stood at $118.6 billion in 2021, then fell by 6.96% to $110.3 billion in 2022, then dropped by 7.82% to $101.7 billion in 2023, then grew by 7.74% to $109.6 billion in 2024, then dropped by 4.27% to $104.9 billion in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $104.9 billion, $105.4 billion, and $107.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.